Acetyl coenzyme A (AcCoA) is the central biosynthetic precursor for fatty-acid synthesis and protein acetylation. In the conventional view of mammalian cell metabolism, AcCoA is primarily generated from glucose-derived pyruvate through the citrate shuttle and ATP citrate lyase in the cytosol [1] [2] [3] . However, proliferating cells that exhibit aerobic glycolysis and those exposed to hypoxia convert glucose to lactate at near-stoichiometric levels, directing glucose carbon away from the tricarboxylic acid cycle and fatty-acid synthesis 4 . Although glutamine is consumed at levels exceeding that required for nitrogen biosynthesis 5 , the regulation and use of glutamine metabolism in hypoxic cells is not well understood. Here we show that human cells use reductive metabolism of a-ketoglutarate to synthesize AcCoA for lipid synthesis. This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is active in most cell lines under normal culture conditions, but cells grown under hypoxia rely almost exclusively on the reductive carboxylation of glutamine-derived a-ketoglutarate for de novo lipogenesis. Furthermore, renal cell lines deficient in the von Hippel-Lindau tumour suppressor protein preferentially use reductive glutamine metabolism for lipid biosynthesis even at normal oxygen levels. These results identify a critical role for oxygen in regulating carbon use to produce AcCoA and support lipid synthesis in mammalian cells.
Acetyl coenzyme A (AcCoA) is the central biosynthetic precursor for fatty-acid synthesis and protein acetylation. In the conventional view of mammalian cell metabolism, AcCoA is primarily generated from glucose-derived pyruvate through the citrate shuttle and ATP citrate lyase in the cytosol [1] [2] [3] . However, proliferating cells that exhibit aerobic glycolysis and those exposed to hypoxia convert glucose to lactate at near-stoichiometric levels, directing glucose carbon away from the tricarboxylic acid cycle and fatty-acid synthesis 4 . Although glutamine is consumed at levels exceeding that required for nitrogen biosynthesis 5 , the regulation and use of glutamine metabolism in hypoxic cells is not well understood. Here we show that human cells use reductive metabolism of a-ketoglutarate to synthesize AcCoA for lipid synthesis. This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is active in most cell lines under normal culture conditions, but cells grown under hypoxia rely almost exclusively on the reductive carboxylation of glutamine-derived a-ketoglutarate for de novo lipogenesis. Furthermore, renal cell lines deficient in the von Hippel-Lindau tumour suppressor protein preferentially use reductive glutamine metabolism for lipid biosynthesis even at normal oxygen levels. These results identify a critical role for oxygen in regulating carbon use to produce AcCoA and support lipid synthesis in mammalian cells.
Although hypoxic cells exhibit a shift towards glycolytic metabolism 4 , a functional electron transport chain and glutamine-derived carbon are required for proliferation of most transformed cells 6 . In line with these studies, we observed increased glutamine consumption when A549 cells were cultured at approximately 1% oxygen while glutamate secretion remained unchanged ( Supplementary Fig. 1a ), indicating that net glutamine consumption was elevated and suggesting that glutamine carbon is used for biosynthesis. Notably, glucose consumption and lactate secretion also increased in these experiments. Consistent with this observation, we found that proliferating cells under both normoxia and hypoxia incorporate glutamine-derived carbon into lipids ( Supplementary Fig. 1b) . Glutamine can contribute carbon to lipogenic AcCoA through two distinct pathways. Cells can oxidatively metabolize glutamine-derived a-ketoglutarate (aKG) in the tricarboxylic acid (TCA) cycle and generate pyruvate from malate by glutaminolysis 5 . Alternatively, some tissues can reductively carboxylate aKG to generate citrate 7, 8 , and recent studies have indicated that the IDH reaction is highly reversible [9] [10] [11] . To determine which pathway cells use to incorporate glutamine carbon into lipids we used stable isotopic tracers [12] [13] [14] . We first cultured several cancer cell lines with [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamine under normoxia and quantified the isotopic label present in metabolite pools along this pathway (Fig. 1a , red carbon atoms). All cells tested with this tracer retained significant label from [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamine in citrate and metabolites downstream of the irreversible ATP citrate lyase reaction, indicating that the reductive flux contributes to the cytosolic AcCoA pool (Supplementary Fig. 2 ). Additional evidence for activity along this pathway was obtained with a uniformly Fig. 3 ).
To quantify the specific contributions of oxidative and reductive glutamine metabolism to fatty-acid synthesis, we cultured cells in the presence of tracers for several days and performed isotopomer spectral analysis (ISA; Supplementary Fig. 4 ) 15 . Use of [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamine specifically allows estimation of the flux of glutamine to lipids through reductive carboxylation (Fig. 1a , blue carbon atoms). Virtually all cell lines cultured with this tracer generated labelled fatty acids, metabolizing glutamine reductively in the TCA cycle to supply 10-25% of their lipogenic AcCoA (Fig. 1b and Supplementary Fig. 5 ). Consistent with these data, we were able to detect 98 6 5 c.p.m. per 10 6 cells in hexane extracts of A549 cells cultured with [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]glutamine. Next we directly compared the contribution of glutamine to fatty acids through the reductive flux as a fraction of the total, the latter determined by using [U- 13 C 5 ]glutamine. In all cell lines tested, including those derived from lung, mammary, colon and squamous cell carcinoma as well as melanoma, glioblastoma and leukaemia, [5] [6] [7] [8] [9] [10] [11] [12] [13] C 5 ]glutamine labelled most of the AcCoA derived from glutamine (Fig. 1b) , highlighting the general use of reductive carboxylation as the primary route through which glutamine, glutamate and aKG carbon are converted to lipids in cultured cells (Fig. 1b and Supplementary Figs 2, 3 and 5). The glutaminolysis pathway is also an important means of glutamine catabolism and can be characterized by quantifying the contribution of glutamine carbon to lactate. Consistent with published reports 5 , glutamine-derived 13 C label was also detected in lactate, and the amount of Fig. 6 ). Mammalian cells express three IDH enzymes encoded by separate genes: IDH1 (cytosolic, NADP 1 -dependent), IDH2 (mitochondrial, NADP 1 -dependent) and the multi-subunit enzyme IDH3 (mitochondrial, NAD 1 -dependent). IDH3 is allosterically regulated and is thought to operate in the oxidative direction. The NADP 1 -dependent isozymes are capable of catalysing the reductive reaction; however, the specific enzyme responsible for this flux is not definitively known 16 . As measurements of metabolite pools in subcellular compartments and labelling therein cannot yet be reliably obtained, we used RNA interference to knockdown expression of IDH1 and IDH2 selectively in A549 cells. Using labelling from [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamine as a readout, we measured a significant and robust decrease in reductive carboxylation when IDH1 messenger RNA (mRNA) was targeted using short hairpin RNAs (shRNAs) (Fig. 1c, d ). These changes were consistent with results using [U-using several cell lines ( Supplementary Fig. 8 ). Finally, we used 13 C metabolic flux analysis 17, 18 to quantify intracellular fluxes using [U- 13 C 5 ]glutamine in A549 cells. The fitted data suggested that reductive IDH flux significantly decreased when IDH1 protein levels were decreased, and this change was the primary alteration observed in the network ( Fig. 1e ; see Supplementary Tables 1-5 for complete results and metabolic flux analysis model description).
Our results suggest that IDH1 can convert NADPH, aKG and CO 2 to isocitrate and NADP 1 in the cytosol. Enzymatic analysis using recombinant protein indicated that IDH1 is indeed capable of consuming NADPH and is responsive to physiological levels of CO 2 (Supplementary Fig. 9 ). Importantly, the proliferation rate of all cell lines with IDH1 knockdown was impaired ( Fig. 1f and Supplementary  Fig. 8 ), indicating that reductive metabolism of aKG in the cytosol may be necessary for robust growth. In contrast to our results with IDH1 shRNAs, we detected no significant change in reductive flux when targeting IDH2 mRNA in A549, MDA-MB-231 and HCT116 cells ( Supplementary Fig. 10 ). Although IDH2 may promote reductive carboxylation in some tissues or conditions, these results are consistent with the proposed role of IDH2 as an oxidative TCA cycle enzyme 19 . Intriguingly, we detected a significant increase in reductive carboxylation activity when culturing cells under hypoxia ( Supplementary  Fig. 11 ). As glucose is usually the primary carbon source for mammalian tissues [1] [2] [3] , we next compared the contributions of reductive glutamine metabolism and glucose oxidation to fatty-acid synthesis by culturing cells with either [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamine or uniformly labelled [U- 13 C 6 ]glucose under normal tissue culture conditions or hypoxia. Strikingly, oxygen levels influenced fatty-acid labelling from both tracers (Fig. 2a, b) . Cells preferentially used glucose carbon for palmitate synthesis under normoxic conditions; however, fatty acids produced under hypoxia were primarily synthesized from glutamine carbon through the reductive pathway. In fact, the reductive carboxylation of glutamine-derived aKG accounted for approximately 80% of the carbon used for de novo lipogenesis in A549 cells growing under hypoxia (Fig. 2c) . Conversely, we detected a concomitant decrease in the contribution of [U- 13 C 6 ]glucose to fatty-acid synthesis under this condition. Significant increases in the relative use of this pathway were observed in all cell lines tested, including non-transformed cells ( Supplementary  Fig. 12 ). In addition, T lymphocytes freshly isolated from a mouse spleen preferentially used reductive glutamine metabolism over glucose oxidation for fatty-acid synthesis when activated under hypoxia (Supplementary Fig. 13 ). Although proliferation rates and relative de novo lipogenesis were lower under hypoxia ( Supplementary Fig. 14a, b) , the net flux of reductive glutamine metabolism to palmitate synthesis was significantly increased in hypoxic cultures (Fig. 2d) . Knockdown of IDH1 protein mitigated the use of reductive glutamine metabolism for lipogenesis under hypoxia ( Supplementary Fig. 14c ). Although most human cells require glutamine for nucleotide and hexosamine biosynthesis, some cell lines can grow in the absence of exogenous sources of glutamine 20 . Remarkably, we found that hypoxia increases the dependence of such cells on glutamine, as evidenced by decreased proliferation in the absence of glutamine and increased reductive glutamine metabolism under hypoxia when glutamine is present ( Fig. 2e and Supplementary Fig. 15 ).
To gain insight into the mechanisms controlling this switch to reductive glutamine metabolism, we analysed changes in the labelling 
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and abundances of TCA cycle metabolites in cells grown under hypoxia. Using [U- 13 C 6 ]glucose, we observed a significant decrease in relative flux through the pyruvate dehydrogenase (PDH) complex ( Fig. 3a and Supplementary Fig. 16a, b) . In addition, the citrate pool became depleted, which would be expected to increase reductive carboxylation flux through mass action ( Fig. 3b and Supplementary  Fig. 16c ). On the other hand, we detected increased amounts of isotopic label in TCA cycle intermediates when using labelled glutamine tracers under hypoxia ( Fig. 3c and Supplementary Fig. 16d , e). Reductively metabolized glutamine accounted for as much as 40-70% of the intracellular citrate, aspartate, malate and fumarate pools when cells were cultured in low oxygen (Fig. 3c) . Given the marked reduction in PDH flux observed in hypoxia, we tested the ability of dichloroacetate (DCA) to restore PDH activity and mitigate the contribution of reductive metabolism to lipogenesis. DCA inhibits pyruvate dehydrogenase kinases (PDKs) 21 , and PDK1 is a known target of HIF-1a that inhibits the activity of PDH through phosphorylation 22, 23 . Although DCA treatment had no observable effect on carbon use under normoxia, reductive glutamine metabolism was inhibited and glucose oxidation was partly restored in A549 cells cultured with DCA under hypoxia ( Fig. 3d and Supplementary Fig. 16f ), suggesting that hypoxia-induced PDK1 expression contributes to the use of reductive carboxylation for fatty-acid synthesis.
The von Hippel-Lindau (VHL) tumour suppressor protein is frequently lost in renal cell carcinoma (RCC) and results in a state of 'pseudohypoxia' by activating HIF signalling [24] [25] [26] . To understand further the role of this pathway in promoting the switch to reductive TCA metabolism we tested RCC cells deficient in VHL using ISA. Remarkably, VHL-deficient RCC cell lines preferentially used reductive glutamine metabolism for lipogenesis, even when cultured under normal oxygen levels, whereas those expressing wild-type (WT) VHL behaved similarly to other carcinoma cell lines (Fig. 4a and Supplementary Fig. 17 ). Re-expression of WT VHL in previously VHL-deficient cell lines resulted in a switch back to oxidative glucose metabolism as the source of carbon for lipid synthesis (Fig. 4b) , reduced extracellular fluxes of glucose, lactate and glutamine (Supplementary Fig. 18a) , and increased the pool of intracellular citrate relative to aKG (Supplementary Fig. 18b ) under normoxia. Furthermore, shRNA-mediated knockdown of HIF-2a partly restored glucosemediated lipogenesis in 786-O cells (Fig. 4c, d ). Consistent with VHL and HIF influencing the switch to reductive glutamine metabolism during hypoxia, glucose entry into the TCA cycle by PDH was increased under normoxia upon introduction of WT VHL or knockdown of HIF2a in 786-O cells (Supplementary Fig. 18c ). Similar changes were observed after knockdown of the HIF-a dimerization partner ARNT (aryl hydrocarbon receptor nuclear translocator) in VHL-deficient normoxic UMRC2 cells, which express both HIF-1a and HIF-2a (ref. 27 ), or after ARNT knockdown in hypoxic A549 and 143B cells (Supplementary Fig. 19) .
Our results highlight an important role for reductive TCA metabolism of glutamine in cell proliferation at physiological oxygen levels RESEARCH LETTER (Fig. 4e) . Given the almost exclusive use of reductive carboxylation for lipogenesis under hypoxia, a redundant or contributing role of mitochondrial IDH2 in this pathway is probable; however, our data provide evidence that the reductive pathway involves IDH1-mediated catalysis in the cytoplasm. Although the carbon source that cells use for lipid synthesis appears to be determined, at least partly, by HIFmediated regulation of PDK1, additional hypoxia-associated changes may also promote reductive glutamine metabolism. For example, HIF-2a enhances c-MYC activity 28 , which in turn drives glutamine catabolism through the regulation of numerous genes including glutaminase 29 . This metabolic reprogramming provides an effective, glucose-independent means of generating AcCoA for biosynthesis. Because glucose is also delivered to cells through the vasculature, it may be limited in microenvironments with decreased oxygen availability 30 . Reductively metabolizing amino acids for lipid synthesis under these conditions would allow cells to conserve glucose for production of ribose and other biosynthetic precursors (for example, one carbon pool, hexosamines) that are not typically generated from other nutrients. Thus, reductive metabolism may allow cells to distribute available nutrients more efficiently in poorly vascularized microenvironments. These results add a new dimension to our understanding of cell metabolism and suggest potential therapeutic targets along the reductive carboxylation and glutamine catabolic pathways that could mitigate hypoxic tumour growth.
METHODS SUMMARY
For determination of steady-state labelling of polar metabolites, cells were cultured for approximately 24 h in the presence of 13 C-labelled glutamine or glucose before extraction. For experiments involving stable isotopic labelling of lipid biomass, cells were grown for approximately 3-5 days in the presence of tracer before extraction. Details of the extraction and derivatization methods are described in the Supplementary Methods. Computational determination of metabolic fluxes, confidence intervals, de novo lipogenesis and the contribution of tracers to fattyacid carbon was accomplished using an in-house software package, Metran 18 . Details of the metabolic networks and gas chromatography/mass spectrometry (GC/MS) measurements used for modelling and complete results are described in Supplementary Information. The generation of cells stably expressing control shRNAs or those targeted IDH1 or IDH2 is described in Supplementary Methods; all experiments were conducted within four passages of initial selection. Hypoxic microenvironments were generated by feeding incubators with a premixed gas composed of 1% O 2 , 5% CO 2 and 94% N 2 , and O 2 levels were confirmed to range between 1 and 3% using a Fyrite combustion analyser. For details of recombinant IDH1 production and enzyme assays, T-cell activation, medium analysis, [5- 
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METHODS
Cell culture, isotopic labelling and hypoxia. All cell lines were cultured in Dulbecco's modified Eagle medium (DMEM; Mediatech) containing 10% fetal bovine serum (FBS; Invitrogen) and 100 U ml 21 penicillin/streptomycin (Mediatech) unless otherwise mentioned. Cell lines were obtained from ATCC unless otherwise noted. The VC3 glioma cell line was provided by T. Lautenschlaeger, MDA-MB-231 and HCT116 cell lines were provided by F. Chiaradonna, MRC5 cells were provided by S. Lippard, SN12C, ACHN and 786-O cells were provided by K. Courtney and L. Cantley, MCF10A cells were provided by J. Brugge and Huh7 cells were provided by M. Hemann. MCF10A cells were cultured in custom DMEM/F12 (Hyclone) containing 5% horse serum, 20 ng ml 21 EGF, 10 mg ml 21 insulin, 100 ng ml 21 cholera toxin, 0.5 mg ml 21 hydrocortisone, 100 U ml 21 penicillin/streptomycin, and labelled/unlabelled glucose and glutamine at 18 mM and 2.5 mM, respectively. PRC3, WT8, pTV and pTR cell lines were subcloned from the 786-O cell line as previously described 31, 32 . For isotopic labelling experiments, cells were cultured in six-well plates in glucose-and glutamine-free DMEM (Sigma) containing 10% dialysed FBS (Invitrogen), 100 U ml 21 penicillin/streptomycin, naturally labelled glucose or glutamine, and the appropriate tracer, including [U- 13 (Supplementary Fig. 20 ). Labelling of fatty acids for ISA was conducted over 3-5 days of culture in an excess of tracer medium (3-4 ml per well in a six-well plate) to prevent nutrient depletion. Hypoxic culture was conducted by feeding a custom mixture of 1% O 2 , 5% CO 2 and 94% N 2 to a standard incubator controlled at 5% CO 2 . HEPES (Mediatech) was added to the culture medium at 20 mM to maintain pH between normoxic and hypoxic cultures. The internal gas content was monitored using Fyrite gas analysers (Bacharach) for CO 2 and O 2 . O 2 levels were confirmed at 1-3% during hypoxic culture. Isolation and culture of primary CD8 1 T lymphocytes. Whole spleens were isolated from OT-1 mice (Jackson Laboratories) expressing ovalbumin (SIINFEKL)-specific T-cell receptors on CD8
1 T cells 33 . Spleens were passed through 40-mm cell strainers, and red blood cells were removed by lysis (ACK buffer, Gibco). Splenocytes were magnetically enriched for CD8
1 T cells by negative selection (Stem Cell Technologies) then suspended in DMEM containing 10% dialysed serum, 100 U ml 21 penicillin/streptomycin and 13 MEM non-essential amino-acid supplement, and labelled/unlabelled glucose (25 mM) and glutamine (4 mM). Cells were cultured for 6 days in 12-well plates under hypoxia and expanded by addition of 10 mg ml 21 SIINFEKL peptide. Media was supplemented with 30 U ml 21 of recombinant interleukin-2 every 48 h, and cells were maintained at a concentration between 1 3 10 6 and 2.5 3 10 6 cells per millilitre by adding additional medium. To verify proliferation, cells were incubated with 2 mM carboxyfluorescein succinimidyl ester (CSFE) in PBS 1 2% FBS for 5 min, washed three times in buffer, re-suspended in media and cultured as above. Viability and T-cell enrichment were determined by flow cytometry after staining with 49,6-diamidino-2-phenylindole (DAPI) and fluorescent anti-CD8 antibody. T-cell proliferation was quantified by flow cytometry using a FACSCanto II equipped with an High Throughput system (Becton Dickinson) and analysed using FlowJo 7.5.5 (TreeStar). Lentiviral-mediated generation of cells with knockdown of IDH1/2. Stable cell cultures with decreased IDH1 and IDH2 expression were generated by lentiviralmediated shRNA expression. pLKO.1 lentiviral vectors targeting IDH1 had shRNA sequences of CCGGGCTGCTTGCATTAAAGGTTTACTCGAGTAAA CCTTTAATGCAAGCAGCTTTTT (IDH1a; TRCN0000027298) and CCGGCG AATCATTTGGGAATTGATTCTCGAGAATCAATTCCCAAATGATTCGTTT TT (IDH1b; TRCN0000027289), IDH2 had shRNA sequence CCGGGTGGA CATCCAGCTAAAGTATCTCGAGATACTTTAGCTGGATGTCCACTTTTT (TRCN0000027225). For controls, either non-targeting control shRNA (SHC002; Sigma) or pLKO.1 scrambled control vector 34 (Addgene) were used. pLKO.1 vector targeting ARNT with shRNA sequence CCGGGAGAAGTCAGATGGTTTATTT CTCGAGAAATAAACCATCTGACTTCTCTTTTT (TRCN0000003819) was obtained from Open Biosystems. HEK293T cells were co-transfected with pLKO.1 vectors and packaging plasmids to produce lentivirus. Filtered supernatants were used for infection, and cells were selected with puromycin (2 mg ml
21
) for at least two passages before initiating tracer and flux experiments. Metabolite extraction and GC/MS analysis. At the conclusion of culture, cells were rinsed with 1 ml ice-cold PBS and quenched with 0.4 ml ice-cold methanol. An equal volume of water was added, and cells were collected in tubes by scraping with a pipette. One volume of ice-cold chloroform was added to each tube, and the extracts were vortexed at 4 uC for 30 min. Samples were centrifuged at 14,000g for 5 min at room temperature. For analysis of polar metabolites, the aqueous phase was transferred to a new tube for evaporation under airflow. For ISA experiments, the non-polar fraction was collected and evaporated under airflow. In some ISA experiments, cells were trypsinized, counted and pelleted before lipid extraction as described above.
Dried polar metabolites were dissolved in 20 ml of 2% methoxyamine hydrochloride in pyridine (Pierce) and held at 37 uC for 1.5 h. After dissolution and reaction, tert-butyldimethylsilyl (TBDMS) derivatization was initiated by adding 30 ml N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide (MBTSTFA) 1 1% tert-butyldimethylchlorosilane (TBDMCS; Pierce) and incubating at 55 uC for 1 h. Fatty-acid methyl esters were generated by dissolving and reacting dried chloroform fractions in 50-100 ml of Methyl-8 reagent (Pierce) and incubating at 60 uC for 1 h. GC/MS analysis was performed using an Agilent 6890 GC equipped with a 30 m DB-35MS capillary column connected to an Agilent 5975B MS operating under electron impact ionization at 70 eV. One microlitre of sample was injected in splitless mode at 270 uC, using helium as the carrier gas at a flow rate of 1 ml min 21 . For measurement of organic and amino acids, the GC oven temperature was held at 100 uC for 3 min and increased to 300 uC at 3.5u min 21 . For analysis of fatty-acid methyl esters, the GC temperature was held at 100 uC for 5 min after injection, increased to 200 uC at 15u min 21 , then to 250 uC at 5u min 21 and finally to 300 uC at 15u min 21 . The MS source and quadrupole were held at 230 uC and 150 uC, respectively, and the detector was run in scanning mode, recording ion abundance in the range of 100-605 m/z. Mass isotopomer distributions were determined by integrating the appropriate ion fragments listed in Supplementary Table 1 . When required, mass isotopomer distributions were corrected for natural isotope abundance using in-house algorithms adapted from ref. 35 . Relative metabolite abundances were measured using a norvaline internal standard and integrating all potentially labelled ions in the metabolite fragments listed in Supplementary  Table 1. ISA and metabolic flux analysis. Computational estimation of fluxes or percentage enrichment in the AcCoA pool and their associated 95% confidence intervals were accomplished using the elementary metabolite unit (EMU)-based software Metran, executed within Matlab (Mathworks) as previously described [36] [37] [38] [39] [40] . Briefly, fluxes were determined iteratively by simulating MS measurements from a given flux vector and comparing with mass isotopomer distribution measurements (three biological replicates). Upon obtaining an acceptable fit, confidence intervals were determined for each flux using parameter continuation. Assumptions, network (including atom transitions), raw data and model fits are presented in Supplementary Information. ISA was performed in a similar manner using the simple network described in Supplementary Fig. 4 and Supplementary Table 6 to determine the tracer enrichment in lipogenic AcCoA (D value) and percentage of newly synthesized lipids and de novo lipogenesis, g(t) (ref. 15) . Uncorrected mass isotopomer distributions, fitted parameters and confidence intervals used for ISA are listed in Supplementary Information. Calculation of absolute flux of tracers to palmitate in biomass. The quantity of newly synthesized palmitate was determined by multiplying the fractional newly synthesized palmitate value (g(t) value from ISA) by the total cellular palmitate. Total cellular palmitate was quantified by GC/MS using a triheptadecanoin internal standard. Flux of a given tracer to palmitate was calculated by multiplying the tracer contribution (D value from ISA) by the amount of newly synthesized palmitate and dividing by the integral viable cell density over the course of the experiment. Detection of 14 C incorporation into lipids. One hundred and fifty thousand A549 cells were plated in DMEM. After attachment, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]glutamine was added to the medium at a final concentration of 1 mCi ml
. After 72 h of growth, lipids were extracted from plates using two rinses of 500 ml hexane:isopropanol (3:2). Three hundred microlitres of PBS was added to induce phase separation and collect the non-polar phase, and an additional 300 ml was added to the hexane fraction to rinse the non-polar fraction. The hexane fraction was dried under nitrogen gas, and the residue was dissolved in 200 ml chloroform before quantifying c.p.m. by liquid scintillation counting. Matched plates of cells were counted to determine cell number. Metabolite analysis of spent medium. Glucose, lactate, glutamine and glutamate concentrations were measured in fresh and spent medium samples using a Yellow Springs Instruments 7100. Cell number was determined using a hemocytometer. Extracellular flux measurements were calculated by assuming exponential growth over the culture period to determine integral viable cell density. Purification of recombinant IDH1. His-tagged IDH1 in pET41a was transformed into Escherichia coli (BL21 plysS DE3) and cells were grown with kanamycin selection to an D 600 nm of 0.6. The cells were then moved to 18 uC and induced with 1 mM IPTG for 16-18 h, pelleted and subjected to freeze/thaw before re-suspension in 60 ml lysis buffer (20 mM Tris, pH 7.4, 0.1% Triton LETTER RESEARCH
